Oncolytics Biotech Inc.

NasdaqCM:ONCY Stock Report

Market Cap: US$71.1m

Oncolytics Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ONCY?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,219,9991.58%
Individual Insiders1,315,6231.71%
General Public74,538,46796.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.

Top Shareholders

Top 25 shareholders own 3.02% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.49%
Bernd Seizinger
380,126US$350.5k0%no data
0.41%
Jonathan M. Rigby
314,863US$290.3k0%no data
0.26%
International Assets Investment Management, LLC
198,400US$182.9k0%0.01%
0.25%
Wayne Pisano
189,941US$175.1k0%no data
0.25%
Seeds Investor LLC
189,941US$175.1k0%0.07%
0.17%
Angela Holtham
127,238US$117.3k0%no data
0.16%
Matthew Coffey
122,654US$113.1k27.3%no data
0.11%
Goldman Sachs Group, Investment Banking and Securities Investments
84,998US$78.4k1.67%no data
0.1%
Citadel Advisors LLC
79,249US$73.1k-42.2%no data
0.097%
Kirk Look
75,128US$69.3k-91.6%no data
0.097%
RBC Dominion Securities Inc., Asset Management Arm
74,496US$68.7k19.6%no data
0.079%
Commonwealth Equity Services, LLC
61,114US$56.4k-3.17%no data
0.075%
Canadian Imperial Bank of Commerce, Asset Management Arm
57,835US$53.3k0%no data
0.064%
Deborah Brown
48,948US$45.1k0%no data
0.054%
Geode Capital Management, LLC
41,942US$38.7k0%no data
0.052%
Long Focus Capital Management LLC
40,000US$36.9k0%no data
0.051%
Thomas Heineman
39,666US$36.6k-92.3%no data
0.049%
BMO Asset Management Corp.
37,924US$35.0k1.33%no data
0.034%
Morgan Stanley, Investment Banking and Brokerage Investments
26,542US$24.5k-80.8%no data
0.034%
SeaCrest Wealth Management, LLC
26,000US$24.0k0%no data
0.032%
Brave Asset Management, Inc.
25,000US$23.1k0%0.01%
0.03%
UBS Asset Management AG
22,936US$21.2k309%no data
0.029%
Newman Dignan & Sheerar, Inc.
22,015US$20.3k0%0.01%
0.028%
National Bank Investments Inc.
21,524US$19.9k-0.8%no data
0.027%
Rovin Capital LLC
20,620US$19.0k0%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 23:36
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncolytics Biotech Inc. is covered by 24 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
John NewmanCanaccord Genuity
Douglas LoeCantor Fitzgerald Canada Corporation